[HTML][HTML] DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Y Handelsman, JE Anderson, GL Bakris… - Metabolism, 2024 - Elsevier
The spectrum of cardiorenal and metabolic diseases comprises many disorders, including
obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular …
obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular …
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
FK Knop, VR Aroda, RD do Vale, T Holst-Hansen… - The Lancet, 2023 - thelancet.com
Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …
Obesity-related kidney disease: current understanding and future perspectives
Obesity is a serious chronic disease and an independent risk factor for the new onset and
progression of chronic kidney disease (CKD). CKD prevalence is expected to increase, at …
progression of chronic kidney disease (CKD). CKD prevalence is expected to increase, at …
A big STEP for treatment of heart failure with preserved ejection fraction
In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart
failure-related symptoms, physical limitations, and exercise function, and reduced …
failure-related symptoms, physical limitations, and exercise function, and reduced …
[HTML][HTML] 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
Background While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being
investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric …
investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric …
Inflammation in obesity-related HFpEF: the STEP-HFpEF program
Background Inflammation is thought to be an important mechanism for the development and
progression of obesity-related heart failure with preserved ejection fraction (HFpEF). In the …
progression of obesity-related heart failure with preserved ejection fraction (HFpEF). In the …
Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?
CM Fuhri Snethlage, D de Wit… - Immunological …, 2024 - Wiley Online Library
Summary Type 1 diabetes (T1D) is a chronic autoimmune disease targeting insulin‐
producing pancreatic beta cells. T1D is a multifactorial disease incorporating genetic and …
producing pancreatic beta cells. T1D is a multifactorial disease incorporating genetic and …
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …
Impact of BMI and comorbidities on efficacy of once‐weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial
BM McGowan, A Houshmand‐Oeregaard… - …, 2023 - Wiley Online Library
Objective This study assessed the effects of semaglutide on body weight, cardiometabolic
risk factors, and glycemic status in individuals categorized by baseline BMI with or without …
risk factors, and glycemic status in individuals categorized by baseline BMI with or without …
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical …
DCD Hope, S Ansari, S Choudhury… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aims To determine whether a continuous infusion of a glucagon‐like peptide receptor (GLP‐
1R)/glucagon receptor (GCGR) co‐agonist, G3215 is safe and well tolerated in adults with …
1R)/glucagon receptor (GCGR) co‐agonist, G3215 is safe and well tolerated in adults with …